Abstract
Common and rare variants in the LRRK2 locus are associated with Parkinson’s disease (PD) risk, but the downstream effects of these variants on protein levels remains unknown. We performed comprehensive proteogenomic analyses using the largest aptamer-based CSF proteomics study to date (7,006 aptamers (6,138 unique proteins) in 3,107 individuals). We identified eleven independent SNPs in the LRRK2 locus associated with the levels of 26 proteins as well as PD risk. Of these, only eleven proteins have been previously associated with PD risk (e.g., GRN or GPNMB). Proteome-wide association study (PWAS) analyses suggested that the levels of ten of those proteins were genetically correlated with PD risk and seven were validated in the PPMI cohort. Mendelian randomization analyses identified five proteins (GPNMB, GRN, HLA-DQA2, LCT, and CD68) causal for PD and nominate one more (ITGB2). These 26 proteins were enriched for microglia-specific proteins and trafficking pathways (both lysosome and intracellular). This study not only demonstrates that protein phenome-wide association studies (PheWAS) and trans-protein quantitative trail loci (pQTL) analyses are powerful for identifying novel protein interactions in an unbiased manner, but also that LRRK2 is linked with the regulation of PD-associated proteins that are enriched in microglial cells and specific lysosomal pathways.
Competing Interest Statement
CC has received research support from: GSK and EISAI. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid Genomics and Circular Genomics. SES has analyzed data provided by C2N Diagnostics to Washington University, but she has not received any research funding or personal compensation from C2N Diagnostics or any other for-profit organizations.
Funding Statement
Funding: This work was supported by grants from the National Institutes of Health (R01AG044546 (CC), P01AG003991(CC, JCM), RF1AG053303 (CC), RF1AG058501 (CC), U01AG058922 (CC), RF1AG074007 (YJS)), the Chuck Zuckerberg Initiative (CZI), the Michael J. Fox Foundation (LI, CC), and the Department of Defense (LI- W81XWH2010849). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444 (JCM), P01AG03991(JCM), and P01AG026276(JCM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Proteomic, pQTL, and raw data from the Knight ADRC participants are available at the NIAGADS and can be accessed at https://www.niagads.org/knight-adrc-collection. Data from the DIAN cohort is available to qualified investigators and can be requested at https://dian.wustl.edu/our-research/for-investigators/diantu-investigator-resources/dian-tu-biospecimen-request-form/. ADNI and PPMI proteomic data can be found at: https://adni.loni.usc.edu/ and, https://www.ppmi-info.org/respectively.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Proteomic, pQTL, and raw data from the Knight ADRC participants are available at the NIAGADS and can be accessed at https://www.niagads.org/knight-adrc-collection. Data from the DIAN cohort is available to qualified investigators and can be requested at https://dian.wustl.edu/our-research/for-investigators/diantu-investigator-resources/dian-tu-biospecimen-request-form/. ADNI and PPMI proteomic data can be found at: https://adni.loni.usc.edu/ and, https://www.ppmi-info.org/respectively.
Abbreviations
- ADNI
- Alzheimer’s Disease Neuroimaging Initiative;
- COJO
- Conditional & Joint Association analysis;
- CSF
- Cerebrospinal fluid;
- DIAN
- Dominantly Inherited Alzheimer Network;
- FDR
- False Discovery Rate;
- GRN
- granulin precursor;
- GWAS
- Genome-wide association study;
- LD
- Linkage disequilibrium;
- MAP
- Memory and Aging Project;
- MR
- Mendelian randomization;
- Pau
- Hospital Sant Pau;
- PheWAS
- Phenome-wide association study;
- PPMI
- Parkinson’s Progression Markers Initiative;
- pQTL
- Protein quantitative trail loci;
- PWAS
- Proteome-wide association studies;
- SNP
- Single nucleotide polymorphism
